Shandong Boan Biotechnology Co (HKSE:06955) Net Income From Continuing Operations : HK$-130.6 Mil (TTM As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Shandong Boan Biotechnology Co Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Shandong Boan Biotechnology Co's net income from continuing operations for the six months ended in Dec. 2023 was HK$-0.1 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-130.6 Mil.

Shandong Boan Biotechnology Co Net Income From Continuing Operations Historical Data

The historical data trend for Shandong Boan Biotechnology Co's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shandong Boan Biotechnology Co Net Income From Continuing Operations Chart

Shandong Boan Biotechnology Co Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Net Income From Continuing Operations

-285.14

-276.02

-370.47

-130.57

Shandong Boan Biotechnology Co Semi-Annual Data
	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Net Income From Continuing Operations	Get a 7-Day Free Trial			-119.37	-179.69	-199.28	-130.46	-0.11

Shandong Boan Biotechnology Co Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-130.6 Mil.

Shandong Boan Biotechnology Co (HKSE:06955) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shandong Boan Biotechnology Co Ltd (HKSE:06955) » Definitions » Net Income From Continuing Operations

Comparable Companies

Traded in Other Exchanges

UJ9:Germany

Address

No. 39 Keji Avenue, High-Tech Industrial Development Zone, Shandong Province, Yantai, CHN

Website

https://www.boan-bio.com

Shandong Boan Biotechnology Co Ltd is a fully integrated biopharmaceutical company. The company is engaged in the development, manufacture, and commercialization of high-quality biologics in China and around the world. It focuses on areas such as oncology, metabolism, autoimmunity, and ophthalmology. Geographically company's revenue is generated from customers located in Mainland China.

Executives

Asiapharm Investments Ltd.
Ginkgo (ptc) Limited
Liu Dianbo
Luye Life Sciences Group Ltd
Luye Pharma Holdings Ltd.
Luye Pharma Hong Kong Limited
Luye Pharmaceutical International Co., Ltd.
Luye Pharmaceutical Investment Co., Ltd.
Nelumbo Investments Limited
Shorea Lbg
Luye Pharma Group Ltd.
Shan Dong Lv Ye Zhi Yao You Xian Gong Si
Yan Tai Lv Ye Yi Yao Kong Gu Ji Tuan You Xian Gong Si
Li Li	2201 Interest of corporation controlled by you

Shandong Boan Biotechnology Co (HKSE:06955) Headlines

No Headlines